Cargando…
First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
BACKGROUND AND AIMS: Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate the ther...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633265/ https://www.ncbi.nlm.nih.gov/pubmed/34693661 http://dx.doi.org/10.1002/cam4.4367 |
_version_ | 1784607893024145408 |
---|---|
author | Shimose, Shigeo Hiraoka, Atsushi Nakano, Masahito Iwamoto, Hideki Tanaka, Masatoshi Tanaka, Takaaki Noguchi, Kazunori Aino, Hajime Ogata, Kei Kajiwara, Masahiko Itano, Satoshi Yokokura, Yoshinori Yamaguchi, Taizo Kawano, Hiroshi Matsukuma, Norito Suga, Hideya Niizeki, Takashi Shirono, Tomotake Noda, Yu Kamachi, Naoki Okamura, Shusuke Kawaguchi, Takumi Koga, Hironori Torimura, Takuji |
author_facet | Shimose, Shigeo Hiraoka, Atsushi Nakano, Masahito Iwamoto, Hideki Tanaka, Masatoshi Tanaka, Takaaki Noguchi, Kazunori Aino, Hajime Ogata, Kei Kajiwara, Masahiko Itano, Satoshi Yokokura, Yoshinori Yamaguchi, Taizo Kawano, Hiroshi Matsukuma, Norito Suga, Hideya Niizeki, Takashi Shirono, Tomotake Noda, Yu Kamachi, Naoki Okamura, Shusuke Kawaguchi, Takumi Koga, Hironori Torimura, Takuji |
author_sort | Shimose, Shigeo |
collection | PubMed |
description | BACKGROUND AND AIMS: Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)‐related HCC. METHODS: We evaluated 504 HCC patients treated with SORA (Study‐1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early‐, mid‐, and late‐term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid‐ and late‐term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study‐2). RESULTS: Overall survival (OS) of HCC patients who received sequential MTA therapy after first‐line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early‐term group, mid‐term group, and the later‐time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study‐1). In Study‐2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin‐bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA. CONCLUSIONS: Sequential therapy with SORA as the first‐line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology. |
format | Online Article Text |
id | pubmed-8633265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86332652021-12-06 First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study Shimose, Shigeo Hiraoka, Atsushi Nakano, Masahito Iwamoto, Hideki Tanaka, Masatoshi Tanaka, Takaaki Noguchi, Kazunori Aino, Hajime Ogata, Kei Kajiwara, Masahiko Itano, Satoshi Yokokura, Yoshinori Yamaguchi, Taizo Kawano, Hiroshi Matsukuma, Norito Suga, Hideya Niizeki, Takashi Shirono, Tomotake Noda, Yu Kamachi, Naoki Okamura, Shusuke Kawaguchi, Takumi Koga, Hironori Torimura, Takuji Cancer Med Clinical Cancer Research BACKGROUND AND AIMS: Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)‐related HCC. METHODS: We evaluated 504 HCC patients treated with SORA (Study‐1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early‐, mid‐, and late‐term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid‐ and late‐term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study‐2). RESULTS: Overall survival (OS) of HCC patients who received sequential MTA therapy after first‐line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early‐term group, mid‐term group, and the later‐time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study‐1). In Study‐2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin‐bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA. CONCLUSIONS: Sequential therapy with SORA as the first‐line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology. John Wiley and Sons Inc. 2021-10-24 /pmc/articles/PMC8633265/ /pubmed/34693661 http://dx.doi.org/10.1002/cam4.4367 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Shimose, Shigeo Hiraoka, Atsushi Nakano, Masahito Iwamoto, Hideki Tanaka, Masatoshi Tanaka, Takaaki Noguchi, Kazunori Aino, Hajime Ogata, Kei Kajiwara, Masahiko Itano, Satoshi Yokokura, Yoshinori Yamaguchi, Taizo Kawano, Hiroshi Matsukuma, Norito Suga, Hideya Niizeki, Takashi Shirono, Tomotake Noda, Yu Kamachi, Naoki Okamura, Shusuke Kawaguchi, Takumi Koga, Hironori Torimura, Takuji First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study |
title | First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study |
title_full | First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study |
title_fullStr | First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study |
title_full_unstemmed | First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study |
title_short | First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study |
title_sort | first‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: a multicenter retrospective study |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633265/ https://www.ncbi.nlm.nih.gov/pubmed/34693661 http://dx.doi.org/10.1002/cam4.4367 |
work_keys_str_mv | AT shimoseshigeo firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT hiraokaatsushi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT nakanomasahito firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT iwamotohideki firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT tanakamasatoshi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT tanakatakaaki firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT noguchikazunori firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT ainohajime firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT ogatakei firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT kajiwaramasahiko firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT itanosatoshi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT yokokurayoshinori firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT yamaguchitaizo firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT kawanohiroshi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT matsukumanorito firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT sugahideya firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT niizekitakashi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT shironotomotake firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT nodayu firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT kamachinaoki firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT okamurashusuke firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT kawaguchitakumi firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT kogahironori firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy AT torimuratakuji firstlinesorafenibsequentialtherapyandliverdiseaseetiologyforunresectablehepatocellularcarcinomausinginverseprobabilityweightingamulticenterretrospectivestudy |